Tags

Type your tag names separated by a space and hit enter

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
Kidney Int. 2003 Jan; 63(1):248-54.KI

Abstract

BACKGROUND

A need exists for a therapy that lowers parathyroid hormone (PTH) without increasing calcium x phosphorus in patients with secondary hyperparathyroidism. The calcimimetic AMG 073 increases the sensitivity of the parathyroid calcium-sensing receptor to extracellular calcium, thereby reducing PTH secretion. Consequently, AMG 073 may provide a novel therapy for secondary hyperparathyroidism.

METHODS

Seventy-eight hemodialysis patients with secondary hyperparathyroidism were enrolled into this 18-week, double-blind, randomized, placebo-controlled, dose titration study. Daily oral AMG 073 doses were administered to determine the effect on PTH, serum calcium, phosphorus, and calcium x phosphorus.

RESULTS

The mean baseline PTH was similar in patients administered AMG 073 or placebo (632 +/- 280.1 pg/mL vs. 637 +/- 455.9 pg/mL, respectively). PTH decreased by 26.0% in the AMG 073-treated group, compared with an increase of 22.0% in the placebo group (P < 0.001). A greater proportion in the AMG 073 group (38%) had a decrease in PTH >or=30%, compared with the placebo group (8%) (P = 0.001). Decreases in PTH were independent of baseline vitamin D usage. Patients receiving AMG 073 had an 11.9% decrease in calcium x phosphorus compared with a 10.9% increase in the placebo group (P < 0.001). Use of vitamin D sterols, as well as both calcium and noncalcium-containing phosphate binders. were similar between treatment groups. Administration of AMG 073 was safe and well tolerated in this 18-week study.

CONCLUSIONS

The calcimimetic AMG 073 decreases both PTH and calcium x phosphorus levels in hemodialysis patients with secondary hyperparathyroidism.

Authors+Show Affiliations

Ochsner Clinical Research Center, New Orleans, Louisiana 70121, USA. jlindberg@ochsner.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12472790

Citation

Lindberg, Jill S., et al. "The Calcimimetic AMG 073 Reduces Parathyroid Hormone and Calcium X Phosphorus in Secondary Hyperparathyroidism." Kidney International, vol. 63, no. 1, 2003, pp. 248-54.
Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003;63(1):248-54.
Lindberg, J. S., Moe, S. M., Goodman, W. G., Coburn, J. W., Sprague, S. M., Liu, W., Blaisdell, P. W., Brenner, R. M., Turner, S. A., & Martin, K. J. (2003). The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney International, 63(1), 248-54.
Lindberg JS, et al. The Calcimimetic AMG 073 Reduces Parathyroid Hormone and Calcium X Phosphorus in Secondary Hyperparathyroidism. Kidney Int. 2003;63(1):248-54. PubMed PMID: 12472790.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. AU - Lindberg,Jill S, AU - Moe,Sharon M, AU - Goodman,William G, AU - Coburn,Jack W, AU - Sprague,Stuart M, AU - Liu,Wei, AU - Blaisdell,Peter W, AU - Brenner,Robert M, AU - Turner,Stewart A, AU - Martin,Kevin J, PY - 2002/12/11/pubmed PY - 2004/3/3/medline PY - 2002/12/11/entrez SP - 248 EP - 54 JF - Kidney international JO - Kidney Int VL - 63 IS - 1 N2 - BACKGROUND: A need exists for a therapy that lowers parathyroid hormone (PTH) without increasing calcium x phosphorus in patients with secondary hyperparathyroidism. The calcimimetic AMG 073 increases the sensitivity of the parathyroid calcium-sensing receptor to extracellular calcium, thereby reducing PTH secretion. Consequently, AMG 073 may provide a novel therapy for secondary hyperparathyroidism. METHODS: Seventy-eight hemodialysis patients with secondary hyperparathyroidism were enrolled into this 18-week, double-blind, randomized, placebo-controlled, dose titration study. Daily oral AMG 073 doses were administered to determine the effect on PTH, serum calcium, phosphorus, and calcium x phosphorus. RESULTS: The mean baseline PTH was similar in patients administered AMG 073 or placebo (632 +/- 280.1 pg/mL vs. 637 +/- 455.9 pg/mL, respectively). PTH decreased by 26.0% in the AMG 073-treated group, compared with an increase of 22.0% in the placebo group (P < 0.001). A greater proportion in the AMG 073 group (38%) had a decrease in PTH >or=30%, compared with the placebo group (8%) (P = 0.001). Decreases in PTH were independent of baseline vitamin D usage. Patients receiving AMG 073 had an 11.9% decrease in calcium x phosphorus compared with a 10.9% increase in the placebo group (P < 0.001). Use of vitamin D sterols, as well as both calcium and noncalcium-containing phosphate binders. were similar between treatment groups. Administration of AMG 073 was safe and well tolerated in this 18-week study. CONCLUSIONS: The calcimimetic AMG 073 decreases both PTH and calcium x phosphorus levels in hemodialysis patients with secondary hyperparathyroidism. SN - 0085-2538 UR - https://wwww.unboundmedicine.com/medline/citation/12472790/The_calcimimetic_AMG_073_reduces_parathyroid_hormone_and_calcium_x_phosphorus_in_secondary_hyperparathyroidism_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0085-2538(15)48866-0 DB - PRIME DP - Unbound Medicine ER -